Clinical Trials
286 trialsCAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
SPiReL
Sunnybrook Health Sciences Centre
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sinocelltech Ltd.
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Ruijin Hospital
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Ruijin Hospital
Glofitamab in Chinese Patients With R/R DLBCL
Peking Union Medical College Hospital
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
Henan Cancer Hospital
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
The First Affiliated Hospital with Nanjing Medical University
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Chengdu Zenitar Biomedical Technology Co., Ltd
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
DALY II Japan
Miltenyi Biomedicine GmbH
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Long-term Study to Evaluate Safety and Persistence of GF-CART01
GenomeFrontier Therapeutics TW Co., Ltd.
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
ODIN
University Health Network, Toronto
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Memorial Sloan Kettering Cancer Center
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Chengdu Zenitar Biomedical Technology Co., Ltd
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
BEB
Insel Gruppe AG, University Hospital Bern
FERTILE
The Lymphoma Academic Research Organisation
ImmunoMRI for Assessment of Tumor-associated Macrophages
Medical University of Vienna
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Ain Shams University
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
C402
Shanghai Exuma Biotechnology Ltd.
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Pell Bio-Med Technology Co., Ltd.
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
The First Affiliated Hospital with Nanjing Medical University
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
The First Affiliated Hospital of Xiamen University